

# Richard Nicholas

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7378951/richard-nicholas-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83  
papers

3,879  
citations

24  
h-index

62  
g-index

86  
ext. papers

4,816  
ext. citations

6.5  
avg, IF

5.12  
L-index

#	Paper	IF	Citations
83	Automated characterisation of microglia in ageing mice using image processing and supervised machine learning algorithms.. <i>Scientific Reports</i> , <b>2022</b> , 12, 1806	4.9	1
82	Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	2
81	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. <i>BMJ Open</i> , <b>2021</b> , 11, e050173	7.3	2
80	Worse Physical Disability Is Associated With the Expression of PD-1 on Inflammatory T-Cells in Multiple Sclerosis Patients With Older Appearing Brains.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 801097	4.1	0
79	Defective CD19+CD24CD38 transitional B-cell function in patients with relapsing-remitting MS. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 1187-1197	5	7
78	Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211020435	5	8
77	Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series. <i>Neurology</i> , <b>2021</b> , 97, e890-e901	6.5	4
76	CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 534-547	5.3	4
75	Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211032510	5	2
74	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 52, 102939	4	12
73	Investigation of the correlation between mildly deleterious mtDNA Variations and the clinical progression of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 53, 103055	4	0
72	Willingness to receive a COVID-19 vaccine in people with multiple sclerosis - UK MS Register survey. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 55, 103175	4	5
71	Intrathecal Inflammation in Progressive Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	14
70	18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2242-2243	8.8	3
69	COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	128
68	Using amyloid PET imaging to diagnose Alzheimer's disease in patients with multiple sclerosis. <i>Journal of Neurology</i> , <b>2020</b> , 267, 3268-3273	5.5	3
67	The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 1145-1156	2.5	4

66	Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 1157-1166	2.5	8
65	B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. <i>Brain Pathology</i> , <b>2020</b> , 30, 779-793	6	33
64	A realist review of advance care planning for people with multiple sclerosis and their families. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240815	3.7	9
63	A Rapid Electronic Cognitive Assessment Measure for Multiple Sclerosis: Validation of Cognitive Reaction, an Electronic Version of the Symbol Digit Modalities Test. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e18234	7.6	3
62	In Response to Letter from Fregonara et al. 2019. <i>Molecular Imaging and Biology</i> , <b>2020</b> , 22, 13-14	3.8	2
61	The impact of the face-to-face consultation on decisional conflict in complex decision-making in multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320959802	2	1
60	Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm. <i>Annals of Neurology</i> , <b>2020</b> , 88, 93-105	9.4	26
59	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> ,	5.5	25
58	A realist review of advance care planning for people with multiple sclerosis and their families <b>2020</b> , 15, e0240815		
57	A realist review of advance care planning for people with multiple sclerosis and their families <b>2020</b> , 15, e0240815		
56	A realist review of advance care planning for people with multiple sclerosis and their families <b>2020</b> , 15, e0240815		
55	A realist review of advance care planning for people with multiple sclerosis and their families <b>2020</b> , 15, e0240815		
54	A realist review of advance care planning for people with multiple sclerosis and their families <b>2020</b> , 15, e0240815		
53	A realist review of advance care planning for people with multiple sclerosis and their families <b>2020</b> , 15, e0240815		
52	Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e562	9.1	7
51	Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11020-11027	11.5	13
50	Initiating disease-modifying treatments in multiple sclerosis: Measuring the decision process using decisional conflict and decisional regret scales. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217319833006	2	5
49	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. <i>Molecular Imaging and Biology</i> , <b>2019</b> , 21, 935-944	3.8	27

48	Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 2150-2163	5.3	28
47	Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosis. <i>Journal of Neuroinflammation</i> , <b>2019</b> , 16, 259	10.1	36
46	Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 653-660	5	30
45	Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. <i>Annals of Neurology</i> , <b>2018</b> , 83, 739-755	9.4	129
44	Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2018</b> , 5, e470	9.1	4
43	Lipoprotein markers associated with disability from multiple sclerosis. <i>Scientific Reports</i> , <b>2018</b> , 8, 17026	4.9	14
42	The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab. <i>Neurology</i> , <b>2018</b> , 91, 572-573	6.5	3
41	Remote Monitoring in the Home Validates Clinical Gait Measures for Multiple Sclerosis. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 561	4.1	15
40	Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions. <i>NeuroImage: Clinical</i> , <b>2017</b> , 13, 9-15	5.3	18
39	Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 1469-1478	5	17
38	Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. <i>Journal of Medical Economics</i> , <b>2017</b> , 20, 962-973	2.4	9
37	C-PBR28 and F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1477-1482	8.9	36
36	[C]PBR-28 positron emission tomography in multiple sclerosis: Neuroinflammation or otherwise?. <i>Annals of Neurology</i> , <b>2017</b> , 81, 323-324	9.4	3
35	A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. <i>Journal of Medical Economics</i> , <b>2017</b> , 20, 474-482	2.4	14
34	Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e384	9.1	3
33	Programmed death 1 is highly expressed on CD8 CD57 T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. <i>Immunology</i> , <b>2017</b> , 152, 660-676	7.8	22
32	A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , <b>2017</b> , 27, 221-226	2.8	27
31	Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002346	11.6	14

30	Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0169546	3.7	2
29	Temporal lobe cortical pathology and inhibitory GABA interneuron cell loss are associated with seizures in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 25-35	5	20
28	Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 117-25	5.5	136
27	The relationship of age with the clinical phenotype in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1750-1758	5	41
26	Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. <i>Wellcome Open Research</i> , <b>2016</b> , 1, 10	4.8	14
25	Peripheral Nerve Dysfunction in Middle-Aged Subjects Born with Thalidomide Embryopathy. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152902	3.7	6
24	Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159310	3.7	5
23	Anti-JC virus antibody titres increase over time with natalizumab treatment. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1833-8	5	28
22	Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. <i>Neuropathology and Applied Neurobiology</i> , <b>2015</b> , 41, 798-813	5.2	62
21	Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. <i>Brain</i> , <b>2015</b> , 138, 110-9	11.2	60
20	Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis. <i>Neurology</i> , <b>2015</b> , 84, 1473-82	6.5	24
19	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. <i>Multiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 83-4	4	4
18	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1112-8	8.9	67
17	Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. <i>Neurobiology of Disease</i> , <b>2014</b> , 65, 203-10	7.5	54
16	Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2014</b> , 383, 2213-21	4.0	283
15	BRAIN VOLUME CHANGE AND DISABILITY IN FINGOLIMOD TRIALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, e4.44-e4	5.5	
14	Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. <i>Brain</i> , <b>2012</b> , 135, 2925-37	11.2	238
13	INFLIXIMAB FOR REFRACTORY NEUROSARCOIDOSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, A21.1-A21	5.5	

12	BG-12 and its potential for the prevention of relapse in multiple sclerosis. <i>Degenerative Neurological and Neuromuscular Disease</i> , <b>2012</b> , 2, 119-132	5.4	1
11	The neuropathological basis of clinical progression in multiple sclerosis. <i>Acta Neuropathologica</i> , <b>2011</b> , 122, 155-70	14.3	148
10	Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. <i>Brain</i> , <b>2011</b> , 134, 2755-71	11.2	531
9	Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. <i>Expert Opinion on Drug Safety</i> , <b>2010</b> , 9, 905-15	4.1	17
8	A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. <i>Annals of Neurology</i> , <b>2010</b> , 68, 477-93	9.4	441
7	Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. <i>Brain</i> , <b>2007</b> , 130, 1089-104	11.2	872
6	Multiple sclerosis. <i>Clinical Evidence</i> , <b>2007</b> , 2007,		2
5	Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. <i>Wellcome Open Research</i> , 1, 10	4.8	11
4	Accelerated brain ageing and disability in multiple sclerosis		9
3	COVID-19 is associated with multiple sclerosis exacerbations that are prevented by disease modifying therapies		1
2	Pre-existing anxiety, depression, and neurological disability is associated with long COVID: A prospective and longitudinal cohort of the United Kingdom Multiple Sclerosis Register		1
1	Associations of DMT therapies with COVID-19 severity in multiple sclerosis		20